
Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated August 24, 2024, titled "Alembic Pharmaceuticals receives USFDA Final Approval for Betamethasone Valerate Foam, 0.12%".
Filed with NSE ·

Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated August 24, 2024, titled "Alembic Pharmaceuticals receives USFDA Final Approval for Betamethasone Valerate Foam, 0.12%".
6ix hasn’t read this filing yet.
Alembic Pharmaceuticals Limited on 6ix
Follow Alembic Pharmaceuticals into a list and get an email when it puts out news.
Follow Alembic Pharmaceuticals